Acceleron To Present At Piper Jaffray Healthcare Conference In December

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the Piper Jaffray 25 th Annual Healthcare Conference to be held on December 3-4, 2013 at the New York Palace in New York, NY.
 
Acceleron speaker:         John Knopf, Ph.D., Chief Executive Officer of Acceleron
Date: Tuesday, December 3, 2013
Time: 3:00 PM (EST)
Location: New York Palace Hotel, New York, NY
 

A live audio webcast of the presentation will be available on the “Events and Presentations” page in the Investors & Media section on the Company’s website ( http://investor.acceleronpharma.com/events.cfm).

A replay of the webcast will be available from Acceleron’s website for thirty days after the conference.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

If you liked this article you might like

Biotech Movers: Acceleron, Clovis, Coherus

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Acceleron Pharma Price Target Raised by Leerink

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting